Garnier helps build NY community garden made from non-recyclable beauty waste
NEW YORK— Garnier, a subsidiary of L’Oréal USA, in partnership with TerraCycle and GrowNYC, announced the groundbreaking of the Garnier Green Garden — the first community garden made from non-recyclable post-consumer beauty waste. The announcement is part of a long-term goal for Garnier to find greener, more sustainable solutions for beauty care products.
On Friday, hundreds of L’Oréal USA employees will participate in a restoration project designed to rebuild a local New York community garden, which was damaged by Hurricane Sandy. When the restoration project is complete, the garden will be turned over to Union Settlement community members and GrowNYC who will grow and maintain food, flowers, and herbs in dozens of newly-installed garden beds made out of recycled beauty materials. The garden is estimated to yield 1,500 pounds of vegetables a year.
"We’re thrilled to have created a program that has the capacity to impact the quality of life for an entire community," stated David Greenberg, president of Maybelline New York-Garnier-Essie. "Our commitment to sustainability isn’t just about keeping packaging waste from personal care and cosmetics products out of landfills, but it’s also about reusing that waste and providing a foundation for greener living."
Garnier spokesperson Bridget Moynahan will be present for the groundbreaking ceremony and activities, as well as representatives from Garnier, L’Oréal USA, TerraCycle, an international upcycling/recycling company that takes difficult-to-recycle packaging and turns it into new products, and GrowNYC, a non-profit that provides environmental solutions throughout New York.
The beauty waste to be used in Garnier’s Green Garden was collected by Garnier’s Personal Care and Beauty Brigade Program, a free fundraising effort that pays for every piece of waste collected and returned to TerraCycle. The collected beauty waste, which would otherwise be destined for landfills, consists of non-recyclable hair care, skin care and cosmetic packaging. These products have since been recycled by TerraCycle to create many of the plastic components being installed in the new garden.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.
Home health care shows strongest job growth in healthcare sector, May data show
WASHINGTON — Most of the growth in jobs in the healthcare sector comes from home health care, according to data released this month by the Bureau of Labor Statistics.
The BLS data found that of the 11,000 or more healthcare jobs added in May, 7,000 were in home health care, while the other 4,000 were in the outpatient care field. Still, leaders in the home health industry have expressed concern about possible policy threats, such as Medicare rebasing. Under the Patient Protection and Affordable Care Act, the Centers for Medicare and Medicaid Services are directed to rebase home health payments between 2014 and 2017, and analyses have indicated that the current trajectory of Medicare home health reimbursements could produce negative margins in 10 states by 2017, according to the Partnership for Quality Home Healthcare, an advocacy organization.
"As the ACA implementation process continues, we urge CMS to carefully consider the important role home health has in the nation’s ongoing employment recovery and the economic state of our sector under current law," PQHH CEO Eric Berger said. "Home health care not only provides vital and cost-effective services to nearly 3.5 million Medicare beneficiaries; it is creating thousands of quality jobs for healthcare professionals."
Actavis partners with Medicines360 to sell low-cost IUDs in public clinics
PARSIPPANY, N.J. — Drug maker Actavis is working with nonprofit pharmaceutical company Medicines360 to make low-cost intrauterine devices available to women, the two said.
The partnership will make the devices available at very low prices to public-sector health clinics around the country. Actavis has licensed U.S. commercial rights for the Medicines360 LNG20 IUD, and Medicines360 retains rights to market the product in the U.S. public sector, including family-planning clinics that provide services to low-income women. Belgian drug maker Uteron Pharma originally developed the device, which is currently in phase-3 clinical trials in the United States and may be launched as early as next year.
"Ensuring patient access to affordable generic pharmaceuticals and specialty brand products that provide consumers with additional treatment options is fundamental to Actavis’ history of leadership in pharmaceuticals," Actavis president for specialty brands Fred Wilkinson said. "Medicines360’s business model, which is unique in ensuring access and affordability, represents a continuation of our commitment to these shared principles."